Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
NCT02794519 · GlaxoSmithKline · PHASE2 · withdrawn · last registry update 2018-08-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study has suspended participant recruitment.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-07-31Also stopped (terminated): GlaxoSmithKline, Sirukumab + Placebo to match sirukumab (NCT02531633)
- 2019-06-11Results posted on the registry: Janssen Research & Development, LLC, Sirukumab 50 mg + Placebo (NCT02473289)
- 2019-05-31Results posted on the registry: GlaxoSmithKline, Sirukumab + Placebo to match sirukumab (NCT02531633)
- 2019-05-06Results posted on the registry: Janssen Research & Development, LLC, Sirukumab 100 mg + Sirukumab 50 mg (NCT01856309)
- 2018-11-19Phase 3 first posted: CSL Behring, Clazakizumab + Physiologic saline solution (NCT03744910)
- 2018-10-09Results posted on the registry: Carla Greenbaum, MD, Siltuximab (NCT02641522)
- 2018-03-29Results posted on the registry: Janssen Research & Development, LLC, Siltuximab (NCT01400503)
- 2018-02-05Results posted on the registry: Janssen Research & Development, LLC, Placebo + Placebo (NCT01606761)
- 2018-01-11Results posted on the registry: Janssen Research & Development, LLC, Placebo + Placebo (NCT01604343)
- 2017-12-04Results posted on the registry: Centocor, Inc., CNTO 136 100 mg + CNTO 136 50 mg (NCT00718718)
- 2017-11-20Also stopped (withdrawn): GlaxoSmithKline, Sirukumab + Placebo to match sirukumab (NCT02899026)
- 2017-09-14Results posted on the registry: Janssen Research & Development, LLC, adalimumab 40 mg + sirukumab 100 mg (NCT02019472)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision